Variability in Bacteremia Prophylaxis Use and Regimens in Pediatric Patients with Leukemia
Abstract
Corresponding Author: Kathryn Carpenter, MD, Boston Children’s Hospital, 300 Longwood Avenue, Mailstop BCH3118, Boston, MA 02115, [email protected], 510-909-4734
Alternate corresponding author: Mari Nakamura, MD, MPH, Boston Children’s Hospital, 300 Longwood Avenue, Mailstop BCH3103, Boston, MA 02115, [email protected], 617-676-5089
No conflicts of interest
Funding/support: Dr. Carpenter received support from the National Institutes of Health [Grant 5T32AI155391-03]. Dr. Nakamura received no additional funding. The sponsors of this work had no role in the study design, conduct, analysis, or interpretation of findings.
Patients receiving chemotherapy for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are at high risk for bacteremia. Based on published evidence, the Children’s Oncology Group (COG) recommends use of levofloxacin prophylaxis in patients with AML and relapsed ALL who receive intensive chemotherapy, but prophylaxis for patients undergoing induction chemotherapy for ALL is not recommended. We conducted a survey of pediatric institutions to characterize the extent and timing of adoption of bacteremia prophylaxis for AML and ALL and assess variability in the antibiotic regimens used.
We distributed the survey via REDCap to US pediatric hospital-based antimicrobial stewardship programs in February – March 2023, identified based on their participation in the Sharing Hospital Antimicrobial Reports for…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.